DE602004029160D1 - - Google Patents

Info

Publication number
DE602004029160D1
DE602004029160D1 DE602004029160T DE602004029160T DE602004029160D1 DE 602004029160 D1 DE602004029160 D1 DE 602004029160D1 DE 602004029160 T DE602004029160 T DE 602004029160T DE 602004029160 T DE602004029160 T DE 602004029160T DE 602004029160 D1 DE602004029160 D1 DE 602004029160D1
Authority
DE
Germany
Prior art keywords
disorder
adenosine
receptor antagonist
phobia
agoraphobia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004029160T
Other languages
English (en)
Inventor
Hiroshi Kase
Naoki Seno
Shizuo Shiozaki
Minoru Kobayashi
Junya Kase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of DE602004029160D1 publication Critical patent/DE602004029160D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004029160T 2003-06-10 2004-06-10 Active DE602004029160D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50904603P 2003-06-10 2003-06-10
US53279303P 2003-12-24 2003-12-24
PCT/JP2004/008486 WO2004108137A1 (en) 2003-06-10 2004-06-10 A method of treating an anxiety disorder

Publications (1)

Publication Number Publication Date
DE602004029160D1 true DE602004029160D1 (de) 2010-10-28

Family

ID=33514319

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004029160T Active DE602004029160D1 (de) 2003-06-10 2004-06-10

Country Status (15)

Country Link
US (2) US8202869B2 (de)
EP (1) EP1631294B1 (de)
JP (1) JP4778894B2 (de)
KR (1) KR20060037252A (de)
CN (1) CN1787821A (de)
AT (1) ATE481101T1 (de)
AU (1) AU2004244906A1 (de)
BR (1) BRPI0411120A (de)
CA (1) CA2528710C (de)
CO (1) CO5640121A2 (de)
DE (1) DE602004029160D1 (de)
EA (1) EA200501924A1 (de)
MX (1) MXPA05013148A (de)
NO (1) NO20055907L (de)
WO (1) WO2004108137A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200400982A1 (ru) * 2002-01-28 2004-12-30 Киова Хакко Когио Ко., Лтд. Способы лечения пациентов, страдающих от нарушения движений
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AU2008279169A1 (en) * 2007-07-23 2009-01-29 Biotie Therapies, Inc 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
US8609162B2 (en) * 2012-10-04 2013-12-17 Invivo Beverages Llc Integrated neuromodulation system for mood enhancement of a living human subject
CN105770563A (zh) * 2016-04-22 2016-07-20 孙建 一种治疗焦虑症的中药制剂及其制备方法
CR20200441A (es) 2018-02-27 2021-03-15 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
TW202402759A (zh) 2018-07-05 2024-01-16 美商英塞特公司 作為a2a/a2b抑制劑之稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator
KR102567684B1 (ko) 2023-01-10 2023-08-18 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치
KR102594242B1 (ko) 2023-01-10 2023-10-27 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3781080T2 (de) * 1986-09-30 1992-12-24 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
JP2928386B2 (ja) * 1992-07-08 1999-08-03 協和醗酵工業株式会社 うつ病治療剤
ATE325610T1 (de) 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
AU756144B2 (en) * 1998-09-22 2003-01-02 Kyowa Hakko Kogyo Co. Ltd. (1,2,4)triazolo(1,5-c)pyrimidine derivatives
EP1177797A1 (de) * 1999-05-12 2002-02-06 Fujisawa Pharmaceutical Co., Ltd. Neue verwendung
KR100520907B1 (ko) * 2000-05-26 2005-10-11 쉐링 코포레이션 아데노신 Ａ2ａ수용체 길항제
MXPA04002389A (es) * 2001-09-13 2004-05-31 Schering Corp Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico.
KR100687954B1 (ko) * 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
US20030119831A1 (en) * 2001-11-20 2003-06-26 Hartz Richard A. 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Also Published As

Publication number Publication date
AU2004244906A1 (en) 2004-12-16
NO20055907L (no) 2005-12-13
US8592420B2 (en) 2013-11-26
BRPI0411120A (pt) 2006-07-18
JP2006527264A (ja) 2006-11-30
CA2528710C (en) 2012-04-17
KR20060037252A (ko) 2006-05-03
EA200501924A1 (ru) 2006-06-30
US20060281770A1 (en) 2006-12-14
EP1631294B1 (de) 2010-09-15
EP1631294A1 (de) 2006-03-08
US8202869B2 (en) 2012-06-19
CO5640121A2 (es) 2006-05-31
CN1787821A (zh) 2006-06-14
US20120232089A1 (en) 2012-09-13
MXPA05013148A (es) 2006-03-17
JP4778894B2 (ja) 2011-09-21
WO2004108137A1 (en) 2004-12-16
ATE481101T1 (de) 2010-10-15
CA2528710A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
CO5640121A2 (es) Un metodo de tratamiento de un trastorno de la ansiedad
NL300933I2 (nl) Letermovir
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
IL249263B (en) A method for extracorporeal organ treatment
ATE490984T1 (de) Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
AU2003272285A1 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
WO2009043051A3 (en) Cd23 binding molecules and methods of use thereof
ES2318119T3 (es) Procedimiento y composiciones para alterar el perfil del efecto edulcorante de la sucralosa.
ATE541859T1 (de) Humane anti-interferon-gamma-antikörper und verfahren zu ihrer verwendung
UA85559C2 (en) Aminobenzophenone compounds
WO2006072348A3 (de) Alkinyl-substituierte thiophene
WO2009150255A3 (en) Markers for predicting response and survival in anti-egfr treated patients
MX2010005047A (es) Inhibidores de aldh-2 en el tratamiento de enfermedades psiquiatricas.
WO2006080549A3 (en) Method and composition for treating central nervous system disorders
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
MX2008002294A (es) Derivados de pirimidina sustituida.
WO2007013962A3 (en) Rapid onset and short term modafinil compositions and methods of use thereof
TW200630357A (en) N-heterocyclylphthaldiamides
WO2007048080A3 (en) Stable pharmaceutical formulations containing escitalopram and bupropion
ATE496047T1 (de) Phenylen-bis-oxazolidin-derivate und ihre verwendung als antikoagulantien
ATE531698T1 (de) 4-aminocarbonylamino-substitutierte imidazolverbindungen mit antiviraler wirkung